Actinium Pharmaceuticals Appoints Matt David as Chief Financial Officer
Actinium Pharmaceuticals has appointed Matt David, M.D., as its new Chief Financial Officer. He will oversee the company's finance, accounting, capital markets, and investor relations functions.
NEW YORK – Actinium Pharmaceuticals has strengthened its leadership team with the appointment of Matt David, M.D., as Chief Financial Officer. Dr. David will lead the company's finance, accounting, capital markets, and investor relations functions.
Dr. David brings over two decades of experience from leadership roles in biopharmaceuticals, healthcare investment banking, and equity research. He joins Actinium from CorMedix Inc., where he most recently served as Executive Vice President and Chief Business Officer. During his tenure at CorMedix, the company received FDA approval for DefenCath® in 2023, launched the product commercially in 2024, and became a diversified, commercial-stage specialty pharmaceutical company.
Actinium Pharmaceuticals is a biopharmaceutical company focused on developing targeted radiotherapies for cancer. The company utilizes a platform for developing radiopharmaceuticals based on actinium-225. Its pipeline includes drug candidates such as ATNM-400 and Actimab-A, aimed at improving outcomes for patients with various cancers.
Prior to CorMedix, Dr. David held leadership positions at Ovid Therapeutics Inc. and spent over a decade in healthcare investment banking. He holds an M.D. from NYU School of Medicine. His appointment is expected to bolster Actinium's financial operations and strategic direction as it advances its pipeline of cancer therapies.